OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MACT.PSX57

Macter International Ltd

PharmaceuticalsVerified

Macter International Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.28, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.84, suggesting it can cover its short-term obligations but with limited excess capacity. Free cash flow is modest at PKR 67.76 million, while operating cash flow is PKR 588.62 million, indicating the company generates sufficient cash from operations to support its liquidity needs. Profitability metrics show a return on equity (ROE) of 21.56% and a return on assets (ROA) of 11.72%, both of which are strong indicators of efficient capital utilization and asset management. These figures are well above the typical thresholds for the pharmaceutical industry, suggesting Macter International Ltd is outperforming its peers in terms of profitability and returns. The company's revenue is primarily concentrated in two segments: Pharmaceuticals and Cosmetics and Fragrance. While the financial data does not provide a breakdown of revenue by segment, the company's operations suggest a strong focus on pharmaceutical contract manufacturing, which is a key driver of its business. Geographically, the company is based in Pakistan, and its exposure is primarily regional, with no disclosed international revenue streams. Macter International Ltd's growth trajectory is not explicitly detailed in the financial data, but the company's operating income of PKR 1.28 billion and net income of PKR 776.43 million suggest a stable performance. The company's capital expenditure of PKR -872.26 million indicates a reduction in investment in new assets, which may signal a focus on maintaining existing operations rather than expanding. The risk assessment for Macter International Ltd highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could pose a challenge in the event of unexpected cash flow disruptions. However, the low dilution risk suggests that the company is not likely to issue additional shares in the near term, preserving shareholder value. Recent events and filings for Macter International Ltd are not detailed in the provided data. However, the company's financial performance and risk profile suggest a stable but cautious approach to capital management and growth. The absence of significant dilution risk and the company's strong profitability metrics indicate a focus on maintaining financial stability and delivering returns to shareholders.

30-day price · MACT.PSX-6.50 (-2.3%)
Low$262.01High$322.00Close$272.50As of14 May, 00:00 UTC
Profile
CompanyMacter International Ltd
TickerMACT.PSX
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Macter International Ltd is a Pakistan-based pharmaceutical company that generates revenue through contract manufacturing and branded generic formulations, including oral solids and liquids, parenterals, topicals, metered dose inhalers, and ear and eye drops.

Classification. Macter International Ltd is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry, with a confidence level of 0.92.

Macter International Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.28, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.84, suggesting it can cover its short-term obligations but with limited excess capacity. Free cash flow is modest at PKR 67.76 million, while operating cash flow is PKR 588.62 million, indicating the company generates sufficient cash from operations to support its liquidity needs. Profitability metrics show a return on equity (ROE) of 21.56% and a return on assets (ROA) of 11.72%, both of which are strong indicators of efficient capital utilization and asset management. These figures are well above the typical thresholds for the pharmaceutical industry, suggesting Macter International Ltd is outperforming its peers in terms of profitability and returns. The company's revenue is primarily concentrated in two segments: Pharmaceuticals and Cosmetics and Fragrance. While the financial data does not provide a breakdown of revenue by segment, the company's operations suggest a strong focus on pharmaceutical contract manufacturing, which is a key driver of its business. Geographically, the company is based in Pakistan, and its exposure is primarily regional, with no disclosed international revenue streams. Macter International Ltd's growth trajectory is not explicitly detailed in the financial data, but the company's operating income of PKR 1.28 billion and net income of PKR 776.43 million suggest a stable performance. The company's capital expenditure of PKR -872.26 million indicates a reduction in investment in new assets, which may signal a focus on maintaining existing operations rather than expanding. The risk assessment for Macter International Ltd highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could pose a challenge in the event of unexpected cash flow disruptions. However, the low dilution risk suggests that the company is not likely to issue additional shares in the near term, preserving shareholder value. Recent events and filings for Macter International Ltd are not detailed in the provided data. However, the company's financial performance and risk profile suggest a stable but cautious approach to capital management and growth. The absence of significant dilution risk and the company's strong profitability metrics indicate a focus on maintaining financial stability and delivering returns to shareholders.
Key takeaways
  • Macter International Ltd has a strong return on equity (21.56%) and return on assets (11.72%), indicating efficient capital and asset utilization.
  • The company maintains a conservative debt-to-equity ratio of 0.28, suggesting a low reliance on debt financing.
  • Macter International Ltd's liquidity position is characterized as medium, with a current ratio of 1.84.
  • The company's free cash flow is modest at PKR 67.76 million, while operating cash flow is PKR 588.62 million.
  • The risk assessment highlights a medium liquidity risk and a low dilution risk.
  • The company's capital expenditure of PKR -872.26 million indicates a reduction in investment in new assets.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyPKR
Revenue$10.36B
Gross profit$4.73B
Operating income$1.28B
Net income$776.4M
R&D
SG&A
D&A
SBC
Operating cash flow$588.6M
CapEx-$872.3M
Free cash flow$67.8M
Total assets$6.62B
Total liabilities$3.02B
Total equity$3.60B
Cash & equivalents
Long-term debt$1.02B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$3.60B
Net cash-$1.02B
Current ratio1.8
Debt/Equity0.3
ROA11.7%
ROE21.6%
Cash conversion76.0%
CapEx/Revenue-8.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricMACT.PSXActivity
Op margin12.3%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin7.5%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin45.6%19.7% medp25 19.7% · p75 39.8%top quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-8.4%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity28.0%71.3% medp25 19.0% · p75 91.7%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 02:32 UTC#fa60c642
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 02:34 UTCJob: 723b7d3e